Reminder: Invitation to Roche ’s virtual event at the 2022 ASCO Annual Meeting focusing on the oncology pipeline
We are pleased to invite investors and analysts to participate in our virtual event onMonday, 6 June 2022, highlighting Roche data presented during the congress scientific program from June 3 – 7 2022 and our early-stage oncology portfolio.16:00 – 17:30 CEST / 15:00 - 16:30 BST09:00 – 10:30 am CDT / 7:00 – 8:30 am PDTThe webinar will start with a presentation, followed by a Q&A session (live access to the speakers).The slides will be available for download at 15:00 CEST on the day of the event.>click hereAgenda Oncology late-stage portfolio updateElena Bernedo-Arzac, SVP, Oncology Therapeutic Area HeadK...
Source: Roche Investor Update - May 30, 2022 Category: Pharmaceuticals Source Type: news
Reminder: Invitation to Roche ’s virtual event at the 2022 ASCO Annual Meeting focusing on the oncology pipeline
We are pleased to invite investors and analysts to participate in our virtual event onMonday,6 June2022, highlighting Roche data presented during the congress scientific program from June 3 – 7 2022 and our early-stage oncology portfolio.16:00 – 17:30 CEST / 15:00 - 16:30BST09:00 – 10:30 am CDT / 7:00 – 8:30 am PDT The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:00 CEST on the day of the event.>click here AgendaOncology late-stageportfolioupdateElenaBernedo-Arzac, SVP, Oncology Therapeutic Area Head ...
Source: Roche Investor Update - May 30, 2022 Category: Pharmaceuticals Source Type: news
New pivotal data demonstrate clinical benefit of Roche ’s glofitamab, a potential first-in-class bispecific antibody for people with aggressive lymphoma
Data to be presented for the first time at ASCO and EHA 2022 show glofitamab induces high and durable complete response rates in people with heavily pre-treated diffuse large B-cell lymphoma ¹ Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphomaGlofitamab is part of Roche ’s industry-leading CD20xCD3 bispecific antibody development programme, which aims to address the diverse needs and preferences of people with blood cancers Basel, 27 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new p...
Source: Roche Investor Update - May 27, 2022 Category: Pharmaceuticals Source Type: news
New pivotal data demonstrate clinical benefit of Roche ’s glofitamab, a potential first-in-class bispecific antibody for people with aggressive lymphoma
Data to be presented for the first time at ASCO and EHA 2022 showglofitamab induces high and durable complete response rates in people with heavily pre-treated diffuse large B-cell lymphoma1Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphomaGlofitamab is part of Roche ’s industry-leading CD20xCD3 bispecific antibody developmentprogramme, which aims to address the diverse needs and preferences of people with blood cancersBasel, 27 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new pivotal data on i...
Source: Roche Investor Update - May 27, 2022 Category: Pharmaceuticals Source Type: news
Roche ’s Polivy combination approved by European Commission for people with previously untreated diffuse large B-cell lymphoma
First new treatment option in more than 20 years to show a clinically meaningful improvement in progression-free survival is approved for people with previously untreated diffuse large B-cell lymphoma (DLBCL)Approval is based on pivotal data from the phase III POLARIX study, where Polivy plus R-CHP significantly improved progression-free survival with comparable safety versus the standard of care, R-CHOPFirst-line treatment with Polivy plus R-CHP has the potential to reduce the burden on patients and healthcare systems, associated with disease progression ¹Basel, 25 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today anno...
Source: Roche Investor Update - May 25, 2022 Category: Pharmaceuticals Source Type: news
Roche ’s Polivy combination approved by European Commission for people with previously untreated diffuse large B-cell lymphoma
First new treatment option in more than 20 years to show a clinically meaningful improvement in progression-free survival is approved for people with previously untreated diffuse large B-cell lymphoma (DLBCL)Approval is based on pivotal data from the phase III POLARIX study, wherePolivy plus R-CHP significantly improved progression-free survival with comparable safety versus the standard of care, R-CHOPFirst-line treatment withPolivy plus R-CHP has the potential to reduce the burden on patients and healthcare systems, associated with disease progression1Basel, 25 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announce...
Source: Roche Investor Update - May 25, 2022 Category: Pharmaceuticals Source Type: news
Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading haematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Onco...
Source: Roche Investor Update - May 24, 2022 Category: Pharmaceuticals Source Type: news
Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure
Almost half of the world ’s population has no or limited access to diagnosticsThis situation is especially acute in low- and middle-income countries (LMICs) where diagnostics plays a critical role for treating and containing the spread of infectious diseases such as Tuberculosis (TB) and HIVNew partnership between Roche and the Global Fund supports low- and middle-income countries in broadening access to diagnostics, helping millions of previously undiagnosed people with TB and HIV get diagnosed and eventually treatedBasel, 12 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY), through its Global Access Program, and The Globa...
Source: Roche Investor Update - May 12, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer
The SKYSCRAPER-01 study evaluatingtiragolumab plusTecentriq did not meet its co-primary endpoint of progression-free survivalThe other co-primary endpoint of overall survival was immature and the study will continue until the next planned analysisThetiragolumab developmentprogramme continues as planned in non-small cell lung cancer and other cancer typesBasel, 11 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from its phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq ® (atezolizumab) versus Tecentriq alone as an initial (first-line) tre...
Source: Roche Investor Update - May 11, 2022 Category: Pharmaceuticals Source Type: news
Reminder: Invitation to Roche ’s virtual ESG event: Access to Healthcare
We are pleased to invite investors and analysts to participate in our virtual event onMonday, 16 May 2022, presenting Roche ’s access to healthcare strategy highlighting initiatives from both the Diagnostics and Pharmaceuticals divisions.15:00 – 16:30 CEST / 14:00 - 15:30 BST09:00 – 10:30 am EDT / 6:00 – 7:30 am PDTThe webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 14:00 CEST on the day of the event.>click hereAgendaWelcomeBruno Eschli, Head of Investor RelationsRoche Sustainability StrategyPascale Schmidt, Chief C...
Source: Roche Investor Update - May 9, 2022 Category: Pharmaceuticals Source Type: news
Invitation to Roche ’s virtual event at the 2022 ASCO Annual Meeting focusing on the oncology pipeline
We are pleased to invite investors and analysts to participate in our virtual event onMonday, 6 June 2022, highlighting Roche data presented during the congress scientific program from June 3 – 7 2022 and our early-stage oncology portfolio.16:00 – 17:30 CEST / 15:00 - 16:30 BST09:00 – 10:30 am CDT / 7:00 – 8:30 am PDT The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:00 CEST on the day of the event. >click hereAccess to virtual event (pre-registration required)Please pre-register for our we...
Source: Roche Investor Update - May 6, 2022 Category: Pharmaceuticals Source Type: news
Save the date: Roche Analyst Event on Diagnostics Division at AACC 2022
We are pleased to invite you to an analyst event onTuesday, 26 July 2022, to discuss Roche ’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting and Clinical Lab Exposition in Chicago, Illinois (July 24-28, 2022).Date/TimeTuesday, 26 July 20226:00pm to 7:15pm Central Daylight Time CDT (Chicago) followed by a buffet reception.VenuePalmer House a Hilton Hotel17 East Monroe Street60603 Chicago, Illinois>mapAn invitation with the detailed program and registration form will soon follow.Best regards, Bruno EschliHead of Investor Relations Bir...
Source: Roche Investor Update - May 2, 2022 Category: Pharmaceuticals Source Type: news
New three-year data for Roche ’s Evrysdi (risdiplam) show long-term improvements in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)
91% of infants treated withEvrysdi in the FIREFISH study were still alive at three yearsInfants treated withEvrysdi maintained or continued to improve in measures of motor function, including their ability to sit without support for 5 and 30 secondsEvrysdi has proven efficacy in infants and adults, with over 5,000 patients treated to dateBasel, 29 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new three-year data from the FIREFISH study, including one-year data from the open label extension, reinforcing the long-term efficacy and safety of Evrysdi ® (risdiplam) in infants with symptomatic Type 1 spinal mu...
Source: Roche Investor Update - April 29, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022
Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Divisionsales up 6%; continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.Diagnostics Divisionsales grow 24% due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.Highlights in the first quarter:FDA approval of Vabysmo (severe eye diseases); CHMP recommends EU approval of Polivy combination (aggressive form of blood cancer), Tecentriq (early-stage non-small cel...
Source: Roche Investor Update - April 25, 2022 Category: Pharmaceuticals Source Type: news
CHMP recommends EU approval of Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resectable Stage II-III NSCLC compared with best supportive careMore than half of people with early-stage NSCLC experience disease recurrence following surgery,1 and most of these recurrent tumours are metastatic, making them incurable2-7If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeBasel, 22 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Commi...
Source: Roche Investor Update - April 22, 2022 Category: Pharmaceuticals Source Type: news
